W Taylor Kimberly1, Bruna Garbugio Dutra2, Anna M M Boers2, Heitor C B R Alves2, Olvert A Berkhemer2,3, Lucie van den Berg4, Kevin N Sheth5, Yvo B W E M Roos4, Aad van der Lugt6, Ludo F M Beenen2, Diederik W J Dippel3, Wim H van Zwam7,8, Robert J van Oostenbrugge8,9, Hester F Lingsma10, Henk Marquering2,11, Charles B L M Majoie2. 1. Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital, Boston. 2. Department of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands. 3. Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 4. Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands. 5. Department of Neurology, Yale New Haven Hospital, New Haven, Connecticut. 6. Department of Radiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 7. Department of Radiology, Maastricht University Medical Center, Maastricht, the Netherlands. 8. Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands. 9. Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands. 10. Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 11. Department of Biomedical Engineering and Physics, Academic Medical Center, Amsterdam, the Netherlands.
Abstract
Importance: It is uncertain whether therapeutic reperfusion with endovascular treatment yields more or less brain edema. Objective: To elucidate the association between reperfusion and brain edema. The secondary objectives were to evaluate whether brain edema could partially be responsible for worse outcomes in patients with later reperfusion or lower Alberta Stroke Program Early Computed Tomography Score. Design, Setting, and Participants: This was a post hoc analysis of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), which was a prospective, randomized, multicenter clinical trial of endovascular treatment compared with conventional care of patients with acute anterior circulation ischemic stroke. Of 502 patients enrolled from December 2010 to June 2014, 2 patients declined to participate. Additionally, exclusion criteria were absence of follow-up imaging or presence of parenchymal hematoma, resulting in 462 patients included in this study. Brain edema was assessed retrospectively, from December 10, 2016, to July 24, 2017, by measuring midline shift (MLS) in all available follow-up scans. Observers were blinded to clinical data. Main Outcomes and Measures: Midline shift was assessed as present or absent and as a continuous variable. Reperfusion status was assessed by the modified thrombolysis in cerebral infarction score in the endovascular treatment arm. The modified arterial occlusive lesion score was used to evaluate the recanalization status in both arms. The modified Rankin scale score at 90 days was used for functional outcome. Results:Of 462 patients, the mean (SD) age was 65 (11) years, and 41.8% (n = 193) were women. Successful reperfusion and recanalization were associated with a reduced likelihood of having MLS (adjusted common odds ratio, 0.25; 95% CI, 0.12-0.53; P < .001 and adjusted common odds ratio, 0.34; 95% CI, 0.21-0.55; P < .001, respectively). Midline shift was partially responsible for worse modified Rankin scale scores in patients without reperfusion or recanalization (MLS changed the logistic regression coefficients by 30.3% and 12.6%, respectively). In patients with delayed reperfusion or lower Alberta Stroke Program Early Computed Tomography Score, MLS mediated part of the worse modified Rankin scale scores, corresponding to a change in the regression coefficient of 33.3% and 64.2%, respectively. Conclusions and Relevance: Successful reperfusion was associated with reduced MLS. This study identifies an additional benefit of reperfusion in relation to edema, as well as rescuing ischemic brain tissue at risk for infarction. Trial Registration: Netherlands Trial Registry number: NTR1804 and Current Controlled Trials number: ISRCTN10888758.
RCT Entities:
Importance: It is uncertain whether therapeutic reperfusion with endovascular treatment yields more or less brain edema. Objective: To elucidate the association between reperfusion and brain edema. The secondary objectives were to evaluate whether brain edema could partially be responsible for worse outcomes in patients with later reperfusion or lower Alberta Stroke Program Early Computed Tomography Score. Design, Setting, and Participants: This was a post hoc analysis of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), which was a prospective, randomized, multicenter clinical trial of endovascular treatment compared with conventional care of patients with acute anterior circulation ischemic stroke. Of 502 patients enrolled from December 2010 to June 2014, 2 patients declined to participate. Additionally, exclusion criteria were absence of follow-up imaging or presence of parenchymal hematoma, resulting in 462 patients included in this study. Brain edema was assessed retrospectively, from December 10, 2016, to July 24, 2017, by measuring midline shift (MLS) in all available follow-up scans. Observers were blinded to clinical data. Main Outcomes and Measures: Midline shift was assessed as present or absent and as a continuous variable. Reperfusion status was assessed by the modified thrombolysis in cerebral infarction score in the endovascular treatment arm. The modified arterial occlusive lesion score was used to evaluate the recanalization status in both arms. The modified Rankin scale score at 90 days was used for functional outcome. Results: Of 462 patients, the mean (SD) age was 65 (11) years, and 41.8% (n = 193) were women. Successful reperfusion and recanalization were associated with a reduced likelihood of having MLS (adjusted common odds ratio, 0.25; 95% CI, 0.12-0.53; P < .001 and adjusted common odds ratio, 0.34; 95% CI, 0.21-0.55; P < .001, respectively). Midline shift was partially responsible for worse modified Rankin scale scores in patients without reperfusion or recanalization (MLS changed the logistic regression coefficients by 30.3% and 12.6%, respectively). In patients with delayed reperfusion or lower Alberta Stroke Program Early Computed Tomography Score, MLS mediated part of the worse modified Rankin scale scores, corresponding to a change in the regression coefficient of 33.3% and 64.2%, respectively. Conclusions and Relevance: Successful reperfusion was associated with reduced MLS. This study identifies an additional benefit of reperfusion in relation to edema, as well as rescuing ischemic brain tissue at risk for infarction. Trial Registration: Netherlands Trial Registry number: NTR1804 and Current Controlled Trials number: ISRCTN10888758.
Authors: W D Heiss; M Huber; G R Fink; K Herholz; U Pietrzyk; R Wagner; K Wienhard Journal: J Cereb Blood Flow Metab Date: 1992-03 Impact factor: 6.200
Authors: Mayank Goyal; Bijoy K Menon; Wim H van Zwam; Diederik W J Dippel; Peter J Mitchell; Andrew M Demchuk; Antoni Dávalos; Charles B L M Majoie; Aad van der Lugt; Maria A de Miquel; Geoffrey A Donnan; Yvo B W E M Roos; Alain Bonafe; Reza Jahan; Hans-Christoph Diener; Lucie A van den Berg; Elad I Levy; Olvert A Berkhemer; Vitor M Pereira; Jeremy Rempel; Mònica Millán; Stephen M Davis; Daniel Roy; John Thornton; Luis San Román; Marc Ribó; Debbie Beumer; Bruce Stouch; Scott Brown; Bruce C V Campbell; Robert J van Oostenbrugge; Jeffrey L Saver; Michael D Hill; Tudor G Jovin Journal: Lancet Date: 2016-02-18 Impact factor: 79.321
Authors: Kevin N Sheth; Jordan J Elm; Bradley J Molyneaux; Holly Hinson; Lauren A Beslow; Gordon K Sze; Ann-Christin Ostwaldt; Gregory J Del Zoppo; J Marc Simard; Sven Jacobson; W Taylor Kimberly Journal: Lancet Neurol Date: 2016-08-23 Impact factor: 44.182
Authors: Ann-Christin Ostwaldt; Thomas W K Battey; Hannah J Irvine; Bruce C V Campbell; Stephen M Davis; Geoffrey A Donnan; W Taylor Kimberly Journal: J Neuroimaging Date: 2018-05-24 Impact factor: 2.486
Authors: Pongpat Vorasayan; Matthew B Bevers; Lauren A Beslow; Gordon Sze; Bradley J Molyneaux; Holly E Hinson; J Marc Simard; Rüdiger von Kummer; Kevin N Sheth; W Taylor Kimberly Journal: Stroke Date: 2019-09-20 Impact factor: 7.914
Authors: Ehsan Dowlati; Kwadwo Sarpong; Stanley Kamande; Austin H Carroll; Jerome Murray; Alynna Wiley; Brendon Peterson; Jeffrey C Mai; Jason J Chang; Edward F Aulisi; Rocco A Armonda; Daniel R Felbaum Journal: Neurol Sci Date: 2021-03-29 Impact factor: 3.307
Authors: W Taylor Kimberly; Bruce C V Campbell; Felix C Ng; Nawaf Yassi; Gagan Sharma; Scott B Brown; Mayank Goyal; Charles B L M Majoie; Tudor G Jovin; Michael D Hill; Keith W Muir; Jeffrey L Saver; Francis Guillemin; Andrew M Demchuk; Bijoy K Menon; Luis San Roman; David S Liebeskind; Philip White; Diederik W J Dippel; Antoni Davalos; Serge Bracard; Peter J Mitchell; Michael J Wald; Stephen M Davis; Kevin N Sheth Journal: Stroke Date: 2021-08-13 Impact factor: 7.914
Authors: Felix C Ng; Leonid Churilov; Nawaf Yassi; Timothy J Kleinig; Vincent Thijs; Teddy Y Wu; Darshan Shah; Helen M Dewey; Gagan Sharma; Patricia M Desmond; Bernard Yan; Mark W Parsons; Geoffrey A Donnan; Stephen M Davis; Peter J Mitchell; Bruce Cv Campbell Journal: J Cereb Blood Flow Metab Date: 2021-05-17 Impact factor: 6.200
Authors: Simiao Wu; Grant Mair; Geoff Cohen; Zoe Morris; Anders von Heijne; Nick Bradey; Lesley Cala; Andre Peeters; Andrew J Farrall; Alessandro Adami; Gillian Potter; Ming Liu; Richard I Lindley; Peter A G Sandercock; Joanna M Wardlaw Journal: Stroke Vasc Neurol Date: 2020-11-27